The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Updates at ASH in CLL: U2
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses his excitement for updates from the UNITY-CLL study which will be presented at ASH 2020. The study compares the safety and efficacy of a combination of the novel anti-CD20 monoclonal antibody, ublituximab, and umbralisib (U2), a novel PI3Kγ inhibitor, with chlorambucil and obinutuzumab in both frontline and relapsed/refractory patients with chronic lymphocytic leukemia (CLL). The study regimen is highly anticipated and has the potential to significantly benefit patients. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Matthew Davids, MD, has participated in scientific advisory boards, has done consultancy work or has received honoraria from AbbVie, Adaptive Biosciences, Ascentage Pharma, AstraZeneca, BeiGene, Celgene, Eli Lilly, Genentech, Janssen, MEI Pharma, Merck, Novartis, Pharmacyclics, TG Therapeutics, Verastem and Research to Practice; and has received research funding from Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma, Novartis, Pharmacyclics, Surface Oncology, TG Therapeutics and Verastem.
